CoChat

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; none of the 85 sources its claims cite is checked for support yet.

Abstract

BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual pro-survival BCL2 family activity. Here, we show that uniquely low BCL-X L expression in melanoma biases the pro-survival pool towards MCL1. Consequently, BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor AZD5991, driving profound tumour cell death that requires BAK/BAX, BIM and BMF, and inhibiting tumour growth in vivo. Combination of ERK1/2 pathway inhibitors with BCL2/BCL-w/BCL-X L inhibitors is stronger in CRC, correlating with a low MCL1:BCL-X L ratio; indeed the MCL1:BCL-X L ratio is predictive of ERK1/2 pathway inhibitor synergy with MCL1 or BCL2/BCL-w/BCL-X L inhibitors. Finally, AZD5991 delays acquired BRAFi/MEKi resistance and enhances the efficacy of an ERK1/2 inhibitor in a model of acquired BRAFi + MEKi resistance. Thus combining ERK1/2 pathway inhibitors with MCL1 antagonists in melanoma could improve therapeutic index and patient outcomes.

Overview

CoChat Summary

TL;DR

Melanoma has a pro-survival BCL2-family pool biased toward MCL1 because BCL-XL is low, so ERK1/2 pathway inhibitors are mainly cytostatic unless MCL1 is also inhibited. Combining BRAF/MEK/ERK inhibitors with the MCL1 inhibitor AZD5991 drives BAK/BAX-, BIM- and BMF-dependent apoptosis, tumour regression, and can delay or overcome acquired BRAFi/MEKi resistance.

Key findings

  • Melanoma cells and patient-derived xenografts show a high MCL1:BCL-XL ratio: the MCL1:BCL-XL mRNA ratio was two- to four-fold higher in melanoma than CRC, NSCLC and pancreatic lineages; absolute protein quantification gave median MCL1:BCL-XL ratios of 5–6 in melanoma vs ~1 in CRC and pancreatic tumour cells and ~2 in NSCLC, and melanoma PDX ratio was ~5 times higher than CRC.
  • BRAFi or MEKi combined with AZD5991 caused strong synergistic killing in melanoma: Loewe synergy scores for trametinib or selumetinib with AZD5991 were >3 times higher in melanoma than CRC, whereas AZD4320 combined better in CRC (>2-fold higher median synergy score); in A375 cells, vemurafenib or selumetinib plus AZD5991 drove ~80% apoptosis.
  • Apoptosis required BAK/BAX and BIM/BMF: BIM or BMF knockout inhibited selumetinib + AZD5991-induced death by ~50% in A375 cells, BIM BMF double knockout reduced it by 65%, and SK-MEL-30 BIM BMF double knockout reduced apoptosis by 60–70%.
  • In vivo, selumetinib + AZD5991 caused regression of established A375 xenografts; AZD5991 delayed acquired resistance, doubling the time to vemurafenib resistance in A375 and WM266-4 cells and increasing time to selumetinib resistance in SK-MEL-30 cells by ~50%, and ERKi + AZD5991 inhibited growth of BRAFi/MEKi-resistant A375 xenografts.

Methods

  • The study used CCLE RNA-seq and TCGA data, western blotting with recombinant protein standards to absolutely quantify MCL1 and BCL-XL in 64 cell lines and in CRC/melanoma PDX tumours, plus immunoprecipitation to assess BIM/BMF binding to MCL1 and BCL-XL.
  • Drug combinations were tested by high-throughput 8 × 8 concentration-matrix assays in 12 melanoma and 12 CRC cell lines, with Loewe synergy scores; mechanistic work used flow cytometry for annexin V, cell cycle, caspase-3/-7 and active BAX, CRISPR/Cas9 BIM/BMF knockout, and isogenic HCT116 BAK/BAX knockout lines.
  • In vivo studies used A375 xenografts in female nude athymic mice and melanoma PDX models in NOD SCID mice, with tumour volume measured by calipers; resistance models were generated by chronic inhibitor exposure and analysed by next-generation sequencing.

Limitations

  • The paper does not include a dedicated limitations section.
  • Evident from the text: much of the mechanistic apoptosis work focuses on A375 and SK-MEL-30 melanoma cells, with HCT116 used for BAK/BAX dependency, so the generality across diverse melanoma genotypes and other lineages is not fully established.
  • Evident from the text: in vivo efficacy is shown in immunodeficient xenograft and PDX models, and AZD5991 is cleared quickly from plasma (2–6 h) with once-weekly dosing, so the clinical durability, optimal schedule and immune contribution remain untested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-019-12409-w

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Low BCL-XL expression in melanoma biases the pro-survival pool towards MCL1. a–c RNA-sequencing mRNA expression data obtained from the Cancer Cell Line Encyclopaedia for MCL1 (a) BCL-XL (BCL2L1) (b) and MCL1:BCL-XL ratio (c) in colorectal cancer (CRC), melanoma, non-small cell lung cancer (NSCLC) and pancreatic tumour cells. Expression values are reads per kilobase million (RPKM) and are presented on a log2 scale. Black lines indicate median values. d, e Seven CRC (left) and seven melanoma (right) cell lines were cultured for 24 h before lysis and western blotting with the indicated antibodies. Quantification (e) of MCL1 and BCL-XL levels relative to A375 cells was performed by quantitative western blotting with fluorescently labelled secondary antibodies. f, g MCL1 (f) and BCL-XL (g) expression were quantified absolutely in CRC, melanoma, NSCLC and pancreatic tumour cell lines using recombinant protein standards and quantitative western blotting with fluorescently labelled secondary antibodies. Each point represents mean expression in a cell line from three independent experiments and is expressed in fmol per µg of total cellular protein (fmol µg−1). Black lines indicate median values. h Ratio of MCL1 to BCL-XL protein calculated from f and g, with black lines indicating median values. i Seven CRC (left) and seven melanoma (right) patient-derived xenograft (PDX) tumours were homogenised in lysis buffer and western blotted with the indicated antibodies. j, k Absolute quantification of MCL1 (j) and BCL-XL (k) expression in CRC and melanoma PDX tumour samples using recombinant protein standards and quantitative western blotting with fluorescently labelled secondary antibodies. Each point represents mean expression in a cell line from at least five technical replicates and is expressed in fmol per µg of total cellular protein (fmol µg−1). Black lines indicate median values. l Ratio of MCL1 to BCL-XL protein calculated from (j) and (k), with black lines indicating median values. Results (e–h, j–l) are the mean of three or more independent experiments, and error bars indicate SD. P ≤ 0.0001 (****), P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤ 0.05 (*), ns (not significant) as determined by Kruskal–Wallis and Dunn’s multiple comparisons tests (a–c, f–h) or two-tailed Mann–Whitney test (j–l)
Fig. 1 Low BCL-XL expression in melanoma biases the pro-survival pool towards MCL1. a–c RNA-sequencing mRNA expression data obtained from the Cancer Cell Line Encyclopaedia for MCL1 (a) BCL-XL (BCL2L1) (b) and MCL1:BCL-XL ratio (c) in colorectal cancer (CRC), melanoma, non-small cell lung cancer (NSCLC) and pancreatic tumour cells. Expression values are reads per kilobase million (RPKM) and are presented on a log2 scale. Black lines indicate median values. d, e Seven CRC (left) and seven melanoma (right) cell lines were cultured for 24 h before lysis and western blotting with the indicated antibodies. Quantification (e) of MCL1 and BCL-XL levels relative to A375 cells was performed by quantitative western blotting with fluorescently labelled secondary antibodies. f, g MCL1 (f) and BCL-XL (g) expression were quantified absolutely in CRC, melanoma, NSCLC and pancreatic tumour cell lines using recombinant protein standards and quantitative western blotting with fluorescently labelled secondary antibodies. Each point represents mean expression in a cell line from three independent experiments and is expressed in fmol per µg of total cellular protein (fmol µg−1). Black lines indicate median values. h Ratio of MCL1 to BCL-XL protein calculated from f and g, with black lines indicating median values. i Seven CRC (left) and seven melanoma (right) patient-derived xenograft (PDX) tumours were homogenised in lysis buffer and western blotted with the indicated antibodies. j, k Absolute quantification of MCL1 (j) and BCL-XL (k) expression in CRC and melanoma PDX tumour samples using recombinant protein standards and quantitative western blotting with fluorescently labelled secondary antibodies. Each point represents mean expression in a cell line from at least five technical replicates and is expressed in fmol per µg of total cellular protein (fmol µg−1). Black lines indicate median values. l Ratio of MCL1 to BCL-XL protein calculated from (j) and (k), with black lines indicating median values. Results (e–h, j–l) are the mean of three or more independent experiments, and error bars indicate SD. P ≤ 0.0001 (****), P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤ 0.05 (*), ns (not significant) as determined by Kruskal–Wallis and Dunn’s multiple comparisons tests (a–c, f–h) or two-tailed Mann–Whitney test (j–l)CC BY · PubMed Central
Fig. 2 ERK1/2 pathway inhibitors combine with the MCL1 inhibitor AZD5991 to kill melanoma cells. a–c A375 (a), SK-MEL-28 (b) and WM266-4 (c) cells were treated with the indicated concentrations of trametinib or vemurafenib in combination with AZD5991 for 5 days. The number of viable cells was determined at the point of treatment (day 0) and at the end of the experiment using Sytox Green. One-hundred percent represents the number of viable cells in the control wells at day 5, 0% is equivalent to the number of viable cells on day 0 and −100% indicates that no viable cells remained on day 5. d, e Twelve melanoma and 12 colorectal cancer (CRC) cell lines were treated with trametinib (Tra) or selumetinib (Sel) and AZD5991 or AZD4320 in an 8 × 8 concentration matrix for 5 days. Viable cell number (determined as above) was used to calculate Loewe synergy scores using the Loewe additivity model. P ≤ 0.01 (**), P ≤ 0.05 (*), ns (not significant) as determined by unpaired or paired two-tailed t-test. f A375 cells were treated with increasing concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 48 h. Cell cycle profile was determined by propidium iodide staining and flow cytometry. g, h A375 cells were treated with increasing concentrations of vemurafenib (Vem) (g) or selumetinib (Sel) (h) with or without 1 μM AZD5991 for 48 h. i The indicated tumour cell lines were treated with DMSO control (C), 1 μM vemurafenib (Vem), 1 μM selumetinib (Sel) and 0.3 μM SCH772984 (SCH) alone or in combination with 1 μM AZD5991, 1 μM AZD4320 and 20 μM Q-VD-OPh (QVD) for 48 h. j–o A375 (j, k), COLO205 (l, m) or SW620 (n, o) cells were treated with increasing concentrations of AZD5991 (j, l, n) or AZD4320 (k, m, o) with or without 1 μM selumetinib (Sel) for 48 h. p, q A375 (p) and SK-MEL-30 (q) cells were treated with increasing concentrations of A-1155463 with or without 1 μM selumetinib (Sel) and 3 μM venetoclax for 48 h. g–q Apoptosis was assessed by Annexin V positivity using flow cytometry. Results (a–q) are the mean of at least three independent experiments and error bars show SD
Fig. 2 ERK1/2 pathway inhibitors combine with the MCL1 inhibitor AZD5991 to kill melanoma cells. a–c A375 (a), SK-MEL-28 (b) and WM266-4 (c) cells were treated with the indicated concentrations of trametinib or vemurafenib in combination with AZD5991 for 5 days. The number of viable cells was determined at the point of treatment (day 0) and at the end of the experiment using Sytox Green. One-hundred percent represents the number of viable cells in the control wells at day 5, 0% is equivalent to the number of viable cells on day 0 and −100% indicates that no viable cells remained on day 5. d, e Twelve melanoma and 12 colorectal cancer (CRC) cell lines were treated with trametinib (Tra) or selumetinib (Sel) and AZD5991 or AZD4320 in an 8 × 8 concentration matrix for 5 days. Viable cell number (determined as above) was used to calculate Loewe synergy scores using the Loewe additivity model. P ≤ 0.01 (**), P ≤ 0.05 (*), ns (not significant) as determined by unpaired or paired two-tailed t-test. f A375 cells were treated with increasing concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 48 h. Cell cycle profile was determined by propidium iodide staining and flow cytometry. g, h A375 cells were treated with increasing concentrations of vemurafenib (Vem) (g) or selumetinib (Sel) (h) with or without 1 μM AZD5991 for 48 h. i The indicated tumour cell lines were treated with DMSO control (C), 1 μM vemurafenib (Vem), 1 μM selumetinib (Sel) and 0.3 μM SCH772984 (SCH) alone or in combination with 1 μM AZD5991, 1 μM AZD4320 and 20 μM Q-VD-OPh (QVD) for 48 h. j–o A375 (j, k), COLO205 (l, m) or SW620 (n, o) cells were treated with increasing concentrations of AZD5991 (j, l, n) or AZD4320 (k, m, o) with or without 1 μM selumetinib (Sel) for 48 h. p, q A375 (p) and SK-MEL-30 (q) cells were treated with increasing concentrations of A-1155463 with or without 1 μM selumetinib (Sel) and 3 μM venetoclax for 48 h. g–q Apoptosis was assessed by Annexin V positivity using flow cytometry. Results (a–q) are the mean of at least three independent experiments and error bars show SDCC BY · PubMed Central
Fig. 3 BRAFi or MEKi combine with AZD5991 to inhibit melanoma cell survival and tumour growth. a A375 cells seeded at low density were treated with DMSO control (C), 2 μM vemurafenib (Vem), 1 μM AZD5991 or the combination for 72 h. b A375 cells seeded at low density were treated with DMSO control (C), 1 μM selumetinib (Sel), 1 μM AZD5991 or the combination for 72 h. c A375 cells seeded at low density were treated with DMSO control (C), 2 μM vemurafenib (Vem), 1 μM AZD4320 or the combination for 72 h. a–c Following treatment cells were washed and grown in inhibitor free medium for a further four days. Colonies were then visualised by crystal violet staining and counted and then growth assessed following solubilisation. Results are mean ± SD of three or more independent experiments. P ≤ 0.0001 (****), P ≤ 0.05 (*) or ns (not significant) as determined by one-way ANOVA and Sidak’s multiple comparisons test. d, e Female nude athymic mice were implanted subcutaneously with A375 cells and randomised 21 days later for dosing with either vehicle-only (Control, n = 5), 25 mg kg−1 selumetinib (Sel, n = 7) twice daily with an 8 h interval, 60 mg kg−1 AZD5991 (n = 7) intravenously once weekly, or the combination of 25 mg kg−1 selumetinib and 60 mg kg−1 AZD5991 (Sel + AZD5991, n = 8) for a further 21 days. Tumour growth was recorded twice weekly and results are mean ± SEM (d) or mean % change in tumour volume ± SEM (e). P ≤ 0.0001 (****), P ≤ 0.001 (***) or P ≤ 0.05 (*), as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons test
Fig. 3 BRAFi or MEKi combine with AZD5991 to inhibit melanoma cell survival and tumour growth. a A375 cells seeded at low density were treated with DMSO control (C), 2 μM vemurafenib (Vem), 1 μM AZD5991 or the combination for 72 h. b A375 cells seeded at low density were treated with DMSO control (C), 1 μM selumetinib (Sel), 1 μM AZD5991 or the combination for 72 h. c A375 cells seeded at low density were treated with DMSO control (C), 2 μM vemurafenib (Vem), 1 μM AZD4320 or the combination for 72 h. a–c Following treatment cells were washed and grown in inhibitor free medium for a further four days. Colonies were then visualised by crystal violet staining and counted and then growth assessed following solubilisation. Results are mean ± SD of three or more independent experiments. P ≤ 0.0001 (****), P ≤ 0.05 (*) or ns (not significant) as determined by one-way ANOVA and Sidak’s multiple comparisons test. d, e Female nude athymic mice were implanted subcutaneously with A375 cells and randomised 21 days later for dosing with either vehicle-only (Control, n = 5), 25 mg kg−1 selumetinib (Sel, n = 7) twice daily with an 8 h interval, 60 mg kg−1 AZD5991 (n = 7) intravenously once weekly, or the combination of 25 mg kg−1 selumetinib and 60 mg kg−1 AZD5991 (Sel + AZD5991, n = 8) for a further 21 days. Tumour growth was recorded twice weekly and results are mean ± SEM (d) or mean % change in tumour volume ± SEM (e). P ≤ 0.0001 (****), P ≤ 0.001 (***) or P ≤ 0.05 (*), as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons testCC BY · PubMed Central
Fig. 4 BRAFi or MEKi combine with AZD5991 to inhibit growth of patient-derived xenografts. a, b MEDI-MEL-10 (a) and MEDI-MEL-07 (b) PDX cell lines were treated with increasing concentrations of trametinib (Tra) with or without 1 μM AZD5991 for 72 h. c, d MEDI-MEL-10 (c) or MEDI-MEL-07 (d) cells were treated with increasing concentrations of AZD5991 with or without 0.3 μM trametinib (Tra) for 72 h. e MEDI-MEL-10 cells were treated with increasing concentrations of AZD4320 with or without 0.3 μM trametinib (Tra) for 72 h. f MEDI-MEL-10 cells were treated with increasing concentrations of A-1155463 with or without 0.3 μM trametinib (Tra) and 3 μM venetoclax for 72 h. a–f Apoptosis was assessed by Annexin V positivity using flow cytometry. Results are mean ± SD of three or more independent experiments. g–n NOD SCID mice were implanted subcutaneously with MEDI-MEL-02 (g–j) or MEDI-MEL-10 (k–n) tumour pieces. Upon reaching 0.15–0.2 cm3 mice were randomised by tumour volume and body mass for dosing (n = 10 per group for MEDI-MEL-02, n = 9 per group for MEDI-MEL-10) with vehicle-only (Control), 20 mg kg−1 vemurafenib (Vem) twice daily with an 8 h interval, 1 mg kg−1 trametinib (Tra) daily, and/or 60 mg kg−1 AZD5991 three times per week, as indicated. Mice were dosed on these schedules throughout the duration of the experiment, except in m and n for which dosing ceased after day 32. Tumour growth was recorded twice weekly and results are mean ± SEM (g, i, k, m) or mean % change in tumour volume ± SEM (h, j, l, n). P ≤ 0.0001 (****), P ≤ 0.001 (***), P ≤ 0.01 (**) or P ≤ 0.05 (*), as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons test
Fig. 4 BRAFi or MEKi combine with AZD5991 to inhibit growth of patient-derived xenografts. a, b MEDI-MEL-10 (a) and MEDI-MEL-07 (b) PDX cell lines were treated with increasing concentrations of trametinib (Tra) with or without 1 μM AZD5991 for 72 h. c, d MEDI-MEL-10 (c) or MEDI-MEL-07 (d) cells were treated with increasing concentrations of AZD5991 with or without 0.3 μM trametinib (Tra) for 72 h. e MEDI-MEL-10 cells were treated with increasing concentrations of AZD4320 with or without 0.3 μM trametinib (Tra) for 72 h. f MEDI-MEL-10 cells were treated with increasing concentrations of A-1155463 with or without 0.3 μM trametinib (Tra) and 3 μM venetoclax for 72 h. a–f Apoptosis was assessed by Annexin V positivity using flow cytometry. Results are mean ± SD of three or more independent experiments. g–n NOD SCID mice were implanted subcutaneously with MEDI-MEL-02 (g–j) or MEDI-MEL-10 (k–n) tumour pieces. Upon reaching 0.15–0.2 cm3 mice were randomised by tumour volume and body mass for dosing (n = 10 per group for MEDI-MEL-02, n = 9 per group for MEDI-MEL-10) with vehicle-only (Control), 20 mg kg−1 vemurafenib (Vem) twice daily with an 8 h interval, 1 mg kg−1 trametinib (Tra) daily, and/or 60 mg kg−1 AZD5991 three times per week, as indicated. Mice were dosed on these schedules throughout the duration of the experiment, except in m and n for which dosing ceased after day 32. Tumour growth was recorded twice weekly and results are mean ± SEM (g, i, k, m) or mean % change in tumour volume ± SEM (h, j, l, n). P ≤ 0.0001 (****), P ≤ 0.001 (***), P ≤ 0.01 (**) or P ≤ 0.05 (*), as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons testCC BY · PubMed Central
Fig. 5 ERK1/2 pathway inhibitors prime melanoma cells for rapid apoptosis following MCL1i. a, b A375 cells were treated with DMSO vehicle-only (Control) or 2 μM vemurafenib (Vem) for 24 h as indicated. One micromolar AZD5991 was then added for the indicated times. Apoptosis was assessed by Annexin V flow cytometry (a), or cells fixed, stained with propidium iodide and cell cycle profile determined by flow cytometry (b). c, d WM266-4 (c) and SK-MEL-30 (d) cells were treated with DMSO vehicle-only (Control), 1 μM vemurafenib (Vem) or 1 μM selumetinib (Sel) for 24 h as indicated. One micromolar AZD5991 was then added for the indicated times and apoptosis assessed by Annexin V staining and flow cytometry. e A375 cells were treated with DMSO vehicle-only (Control) or 1 μM selumetinib (Sel) for 24 h. One micromolar AZD5991 was then added for the indicated times and relative caspase-3/-7 activity measured. f A375 cells were treated with DMSO vehicle-only (Control) or 1 μM selumetinib (Sel) for 24 h followed by combination with 1 μM AZD5991 for the indicated times. BAX activation was determined using anti-BAX antibody clone 6A7, an N-terminal antibody specific for an active conformation of BAX, and flow cytometry. A representative flow cytometer trace is shown (left) alongside pooled results (right). g HCT116, HCT116 BAK KO, HCT116 BAX KO and HCT116 BAK BAX DKO isogenic cell lines were lysed and western blotted with the indicated antibodies. h, i HCT116, HCT116 BAK KO, HCT116 BAX KO and HCT116 BAK BAX DKO isogenic cell lines were treated with DMSO control (C), 2 μM selumetinib (Sel), 1 μM AZD5991 or 2 μM selumetinib plus 1 μM AZD5991 (Sel + AZD5991) with or without 20 μM Q-VD-OPh (Sel + AZD5991 + QVD) for 48 h, and cell death assessed by Annexin V (h) or PI (i) staining and flow cytometry. Results (a–f, h, i) are mean ± SD of three or more independent experiments. P ≤ 0.0001 (****) and ns (not significant) as determined by two-way ANOVA and Tukey’s multiple comparisons test
Fig. 5 ERK1/2 pathway inhibitors prime melanoma cells for rapid apoptosis following MCL1i. a, b A375 cells were treated with DMSO vehicle-only (Control) or 2 μM vemurafenib (Vem) for 24 h as indicated. One micromolar AZD5991 was then added for the indicated times. Apoptosis was assessed by Annexin V flow cytometry (a), or cells fixed, stained with propidium iodide and cell cycle profile determined by flow cytometry (b). c, d WM266-4 (c) and SK-MEL-30 (d) cells were treated with DMSO vehicle-only (Control), 1 μM vemurafenib (Vem) or 1 μM selumetinib (Sel) for 24 h as indicated. One micromolar AZD5991 was then added for the indicated times and apoptosis assessed by Annexin V staining and flow cytometry. e A375 cells were treated with DMSO vehicle-only (Control) or 1 μM selumetinib (Sel) for 24 h. One micromolar AZD5991 was then added for the indicated times and relative caspase-3/-7 activity measured. f A375 cells were treated with DMSO vehicle-only (Control) or 1 μM selumetinib (Sel) for 24 h followed by combination with 1 μM AZD5991 for the indicated times. BAX activation was determined using anti-BAX antibody clone 6A7, an N-terminal antibody specific for an active conformation of BAX, and flow cytometry. A representative flow cytometer trace is shown (left) alongside pooled results (right). g HCT116, HCT116 BAK KO, HCT116 BAX KO and HCT116 BAK BAX DKO isogenic cell lines were lysed and western blotted with the indicated antibodies. h, i HCT116, HCT116 BAK KO, HCT116 BAX KO and HCT116 BAK BAX DKO isogenic cell lines were treated with DMSO control (C), 2 μM selumetinib (Sel), 1 μM AZD5991 or 2 μM selumetinib plus 1 μM AZD5991 (Sel + AZD5991) with or without 20 μM Q-VD-OPh (Sel + AZD5991 + QVD) for 48 h, and cell death assessed by Annexin V (h) or PI (i) staining and flow cytometry. Results (a–f, h, i) are mean ± SD of three or more independent experiments. P ≤ 0.0001 (****) and ns (not significant) as determined by two-way ANOVA and Tukey’s multiple comparisons testCC BY · PubMed Central
Fig. 6 Apoptosis induced by combined ERK1/2 pathway and MCL1 inhibition requires BIM and BMF. a A375 cells were treated with the indicated concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 24 h. b SK-MEL-30 cells were treated with the indicated concentrations of selumetinib (Sel) with or without 1 μM AZD5991 for 24 h. c A375 cells were treated with the indicated concentrations of AZD5991 with or without 1 μM vemurafenib (Vem) for 24 h. d SK-MEL-30 cells were treated with the indicated concentrations of AZD5991 with or without 1 μM selumetinib (Sel) for 24 h. a–d Whole-cell lysates were western blotted with the indicated antibodies. e, f A375 cells and three independent clonally derived WT, BIM KO, BMF KO and BIM BMF DKO A375 CRISPR clones were treated with 1 μM selumetinib (Sel) as indicated for 24 h and BIM and BMF expression assessed by western blotting (e) or treated with DMSO-only control (C), 1 μM selumetinib (Sel), 1 μM AZD5991 or 1 μM selumetinib plus 1 μM AZD5991 (Sel + AZD5991) as indicated for 48 h and apoptosis assessed by Annexin V staining and flow cytometry (f). Results (f) show mean ± SD of three independent experiments. P ≤ 0.0001 (****), P ≤ 0.01 (**) and ns (not significant) as determined by two-way ANOVA and Tukey’s multiple comparisons test. g, h SK-MEL-30 cells and three independent clonally derived WT and BIM BMF DKO SK-MEL-30 CRISPR clones were treated with 1 μM selumetinib (Sel) as indicated for 24 h and BIM and BMF expression assessed by western blotting (g) or treated with DMSO-only control (C), 1 μM selumetinb (Sel), 1 μM AZD5991 or 1 μM selumetinib plus 1 μM AZD5991 (Sel + AZD5991) as indicated for 48 h and apoptosis assessed by Annexin V staining and flow cytometry (h). Results (h) show mean ± SD of three independent experiments. P ≤ 0.0001 (****) as determined by two-way ANOVA and Tukey’s multiple comparisons test
Fig. 6 Apoptosis induced by combined ERK1/2 pathway and MCL1 inhibition requires BIM and BMF. a A375 cells were treated with the indicated concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 24 h. b SK-MEL-30 cells were treated with the indicated concentrations of selumetinib (Sel) with or without 1 μM AZD5991 for 24 h. c A375 cells were treated with the indicated concentrations of AZD5991 with or without 1 μM vemurafenib (Vem) for 24 h. d SK-MEL-30 cells were treated with the indicated concentrations of AZD5991 with or without 1 μM selumetinib (Sel) for 24 h. a–d Whole-cell lysates were western blotted with the indicated antibodies. e, f A375 cells and three independent clonally derived WT, BIM KO, BMF KO and BIM BMF DKO A375 CRISPR clones were treated with 1 μM selumetinib (Sel) as indicated for 24 h and BIM and BMF expression assessed by western blotting (e) or treated with DMSO-only control (C), 1 μM selumetinib (Sel), 1 μM AZD5991 or 1 μM selumetinib plus 1 μM AZD5991 (Sel + AZD5991) as indicated for 48 h and apoptosis assessed by Annexin V staining and flow cytometry (f). Results (f) show mean ± SD of three independent experiments. P ≤ 0.0001 (****), P ≤ 0.01 (**) and ns (not significant) as determined by two-way ANOVA and Tukey’s multiple comparisons test. g, h SK-MEL-30 cells and three independent clonally derived WT and BIM BMF DKO SK-MEL-30 CRISPR clones were treated with 1 μM selumetinib (Sel) as indicated for 24 h and BIM and BMF expression assessed by western blotting (g) or treated with DMSO-only control (C), 1 μM selumetinb (Sel), 1 μM AZD5991 or 1 μM selumetinib plus 1 μM AZD5991 (Sel + AZD5991) as indicated for 48 h and apoptosis assessed by Annexin V staining and flow cytometry (h). Results (h) show mean ± SD of three independent experiments. P ≤ 0.0001 (****) as determined by two-way ANOVA and Tukey’s multiple comparisons testCC BY · PubMed Central
Fig. 7 Combined BRAFi and MCL1i redistributes BIM and BMF to other pro-survival proteins. a A375 cells were treated with DMSO vehicle-only (C and 5991) or 2 μM vemurafenib (Vem and Vem + 5991) for 24 h followed by DMSO-only (C and Vem) or 1 μM AZD5991 (5991 and Vem + 5991) for a further 4 h. Lysates (input) were subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant unbound fractions (UNB) were then western blotted using the indicated antibodies. b A375 cells were treated with DMSO vehicle-only (C and 1155) or 2 μM vemurafenib (Vem and Vem + 1155) for 24 h followed by DMSO-only (C and Vem) or 0.1 μM A-1155463 (1155 and Vem + 1155) for a further 4 h. Lysates (input) were subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant unbound fractions (UNB) were then western blotted using the indicated antibodies
Fig. 7 Combined BRAFi and MCL1i redistributes BIM and BMF to other pro-survival proteins. a A375 cells were treated with DMSO vehicle-only (C and 5991) or 2 μM vemurafenib (Vem and Vem + 5991) for 24 h followed by DMSO-only (C and Vem) or 1 μM AZD5991 (5991 and Vem + 5991) for a further 4 h. Lysates (input) were subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant unbound fractions (UNB) were then western blotted using the indicated antibodies. b A375 cells were treated with DMSO vehicle-only (C and 1155) or 2 μM vemurafenib (Vem and Vem + 1155) for 24 h followed by DMSO-only (C and Vem) or 0.1 μM A-1155463 (1155 and Vem + 1155) for a further 4 h. Lysates (input) were subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant unbound fractions (UNB) were then western blotted using the indicated antibodiesCC BY · PubMed Central
Fig. 8 AZD5991 can delay and overcome acquired resistance to BRAFi and/or MEKi. a A375 and PLX4720/selumetinib-resistant A375 (A375 PLX/Sel-R2) cells were washed and treated with 0.3 μM SCH772984 (SCH), 1 μM AZD5991 (5991) or the combination (SCH + 5991) for 48 h, either in the presence (PLX + Sel) or the absence of 0.66 μM PLX4720 and 0.5 μM selumetinib, their normal growth medium. Cell cycle profile was determined by propidium iodide staining and flow cytometry. Results show mean ± SD of four independent experiments. b Female athymic nude mice were injected subcutaneously with A375 PLX/Sel-R2 cells. Once tumours reached an average of 0.2 cm3, mice were randomised in to treatment groups and dosed with vehicle-only (Control, n = 10), 50 mg kg−1 AZ13776197 (AZ6197, n = 10) orally once daily, 60 mg kg−1 AZD5991 (AZD5991, n = 10) once weekly intravenously, or the combination of 50 mg kg−1 AZ6197 and 60 mg kg−1 AZD5991 (AZ6197 + AZD5991, n = 10). Tumour volume growth results are geometric mean ± SEM. P ≤ 0.01 (**) as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons test. c A375 cells were cultured in the presence of DMSO-only (Control), 2 μM vemurafenib (Vem), 1 μM AZD5991 or the combination (Vem + AZD5991) and the number of cumulative doublings recorded. Three independent experiments are shown. d A375, vemurafenib-resistant A375 (Vem-R1) cells, AZD5991-resistant A375 (5991-R1) cells and vemurafenib/AZD5991-resistant A375 (Vem/5991-R1) cells were treated with 2 μM vemurafenib (Vem), 1 μM AZD5991 (5991) with or without 1 μM SCH772984 (SCH) as indicated for 48 h. Cell cycle profile was determined by propidium iodide staining and flow cytometry. Results show mean ± SD of three independent experiments. e A375, Vem-R1, 5991-R1 and Vem/5991-R1 were washed and treated with 2 μM vemurafenib (Vem) and/or 1 μM AZD5991 (5991) as indicated for 24 h. Whole-cell lysates were western blotted with the indicated antibodies. f WM266-4 cells were cultured in the presence of DMSO-only (Control), 1 μM vemurafenib, 1 μM AZD5991 or Vem + AZD5991 and the number of cumulative doublings recorded. g SK-MEL-30 cells were cultured in the presence of DMSO-only (Control), 1 μM selumetinib (Sel), 1 μM AZD5991 or Sel + AZD5991 for 16 weeks and the number of cumulative doublings recorded
Fig. 8 AZD5991 can delay and overcome acquired resistance to BRAFi and/or MEKi. a A375 and PLX4720/selumetinib-resistant A375 (A375 PLX/Sel-R2) cells were washed and treated with 0.3 μM SCH772984 (SCH), 1 μM AZD5991 (5991) or the combination (SCH + 5991) for 48 h, either in the presence (PLX + Sel) or the absence of 0.66 μM PLX4720 and 0.5 μM selumetinib, their normal growth medium. Cell cycle profile was determined by propidium iodide staining and flow cytometry. Results show mean ± SD of four independent experiments. b Female athymic nude mice were injected subcutaneously with A375 PLX/Sel-R2 cells. Once tumours reached an average of 0.2 cm3, mice were randomised in to treatment groups and dosed with vehicle-only (Control, n = 10), 50 mg kg−1 AZ13776197 (AZ6197, n = 10) orally once daily, 60 mg kg−1 AZD5991 (AZD5991, n = 10) once weekly intravenously, or the combination of 50 mg kg−1 AZ6197 and 60 mg kg−1 AZD5991 (AZ6197 + AZD5991, n = 10). Tumour volume growth results are geometric mean ± SEM. P ≤ 0.01 (**) as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons test. c A375 cells were cultured in the presence of DMSO-only (Control), 2 μM vemurafenib (Vem), 1 μM AZD5991 or the combination (Vem + AZD5991) and the number of cumulative doublings recorded. Three independent experiments are shown. d A375, vemurafenib-resistant A375 (Vem-R1) cells, AZD5991-resistant A375 (5991-R1) cells and vemurafenib/AZD5991-resistant A375 (Vem/5991-R1) cells were treated with 2 μM vemurafenib (Vem), 1 μM AZD5991 (5991) with or without 1 μM SCH772984 (SCH) as indicated for 48 h. Cell cycle profile was determined by propidium iodide staining and flow cytometry. Results show mean ± SD of three independent experiments. e A375, Vem-R1, 5991-R1 and Vem/5991-R1 were washed and treated with 2 μM vemurafenib (Vem) and/or 1 μM AZD5991 (5991) as indicated for 24 h. Whole-cell lysates were western blotted with the indicated antibodies. f WM266-4 cells were cultured in the presence of DMSO-only (Control), 1 μM vemurafenib, 1 μM AZD5991 or Vem + AZD5991 and the number of cumulative doublings recorded. g SK-MEL-30 cells were cultured in the presence of DMSO-only (Control), 1 μM selumetinib (Sel), 1 μM AZD5991 or Sel + AZD5991 for 16 weeks and the number of cumulative doublings recordedCC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 43 Not checked · 148 Own results and interpretations

108 more claims

Create a free account to see all 192 claims and to verify the 79 references still open.

See all claims — free account
  • It may state two separate claims as one. 69
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Citations

Cites

Show all 60 references

Cited by

See all 81

Metadata

Authors
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., Markovets, A., Dry, J. R., Drew, L., Flemington, V., Proia, T., Jodrell, D. I., Smith, P. D., & Cook, S. J.
Affiliations
  • Babraham Institute (GB)
  • AstraZeneca (United States) (US)
  • University of Cambridge (GB)
  • AstraZeneca (United Kingdom) (GB)
  • Cancer Research UK (GB)
Corresponding author
  • Sale, Matthew J.
  • Cook, Simon J.
Venue
Nature Communications
Published
2019-11-14
Volume
10
Issue
1
Pages
5167-5167
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2953122837
Cited by
80
References
60
Citations by year
2026: 5 · 2025: 11 · 2024: 9 · 2023: 10 · 2022: 11 · 2021: 16 · 2020: 18
FWCI
3.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo
  • Apollo (cc-by)
Funders
  • Cancer Research UK (A14867)
  • RCUK | Biotechnology and Biological Sciences Research Council (BB/J004456/1, BB/P013384/1, BBS/E/B000C0433, BBS/E/B/000C0434)
  • AstraZeneca
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
melanoma, Mcl-1, Bcl-xL, BRAF inhibitors, MEK inhibitors, AZD5991, synthetic lethality, apoptosis, building information modeling, BMF, acquired drug resistance, colorectal cancer, Bcl-2 family proteins, combination therapy, predictive biomarkers
MeSH terms
Animals, Cell Survival, Humans, Melanoma, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System, Cell Line, Tumor, Macrocyclic Compounds, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, bcl-X Protein, Mice, Molecular Targeted Therapy, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. https://app.cochat.ai/papers/10.1038/s41467-019-12409-w
The paper
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., Markovets, A., Dry, J. R., Drew, L., Flemington, V., Proia, T., Jodrell, D. I., Smith, P. D., & Cook, S. J. (2019). Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications. https://doi.org/10.1038/s41467-019-12409-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.